Healthcare professionals who specialize in managing spinal muscular atrophy (SMA) are prone to putting off tasks related to patient…
Articles by Lila Levinson, PhD
Using wearable sensors during clinical tests may help doctors objectively measure changes in movement ability for people with spinal…
Problems with swallowing, also called dysphagia, remain a concern for many children with spinal muscular atrophy (SMA) type 1…
The use of disease-modifying therapies (DMTs) — all widely approved in the last 10 years — may help children…
The motor function benefits of Itvisma (onasemnogene abeparvovec-brve), one of two Novartis’ gene therapies for spinal muscular…
Up to three years of treatment with Evrysdi (risdiplam) appears safe and was associated with presymptomatic children with…
A high-dose regimen of Spinraza (nusinersen) that is up for regulatory approval in the U.S. may help stabilize or…
Salanersen, a treatment candidate for spinal muscular atrophy (SMA) now in clinical testing, is safe and was shown…
Genetic screening for spinal muscular atrophy (SMA) in newborns may allow treatment to begin earlier, which could help support…
Apitegromab, a muscle-strengthening therapy for spinal muscular atrophy (SMA), helped improve motor function in a new analysis of…